Home The Word Brain My Amedeo FAQ Privacy About


Amedeo Chinese

For Medical Students & Physicians

A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever.

Download the free PDF: Amedeo Chinese PDF

  Leukemia

  Free Subscription


21.09.2026

1 Acta Haematol
2 Am J Hematol
5 Ann Hematol
3 Blood
3 Cancer
1 Cancer Chemother Pharmacol
2 Exp Hematol
2 Int J Hematol
1 J Clin Oncol
3 Leuk Lymphoma
1 Leuk Res
1 Leukemia
2 N Engl J Med


   Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    Acta Haematol

  1. YOUSEFI A, Levin MD, Westerweel PE
    The Prevalence and Clinical Impact of Bone Marrow Fibrosis in Chronic Myeloid Leukemia.
    Acta Haematol. 2026 Sep 17:1-6. doi: 10.1159/000553020.
    PubMed         Abstract available


    Am J Hematol

  2. KUMAR S, Warraich M, Fatima M, McCullough K, et al
    Venetoclax Plus Hypomethylating Agent for 7- Versus 14- Versus 21- Versus 28-Day Cycles in Newly-Diagnosed Acute Myeloid Leukemia: ELN and Mayo Genetic Risk-Stratified Analysis in 540 Patients.
    Am J Hematol. 2026 Sep 17. doi: 10.1002/ajh.70500.
    PubMed         Abstract available

  3. TROUSSARD X, Maitre E, Paillassa J
    Hairy Cell Leukemia: 2026 Update on Diagnosis, Risk-Stratification, and Treatment.
    Am J Hematol. 2026 Sep 15. doi: 10.1002/ajh.70441.
    PubMed         Abstract available


    Ann Hematol

  4. DUZENLI KAR Y, Oren H, Sezgin Evim M, Zengin E, et al
    Outcomes of down syndrome-related myeloid leukemia in Turkiye: a multicenter retrospective observational cohort study by the Turkish Pediatric Hematology Association.
    Ann Hematol. 2026;105:422.
    PubMed         Abstract available

  5. LYU C, Meng H, Pu Y, Luan X, et al
    Chidamide plus venetoclax as effective and safe maintenance therapy in high-risk acute myeloid leukemia and myelodysplastic syndrome post-transplantation.
    Ann Hematol. 2026;105:420.
    PubMed         Abstract available

  6. GINOSYAN AA, Ashouri K, Cheng J, Ford L, et al
    Optimizing venetoclax duration with hypomethylating agents for newly diagnosed acute myeloid leukemia: impact on response and survival.
    Ann Hematol. 2026;105:415.
    PubMed         Abstract available

  7. ALIBRAHIM MN, Elsayed MA, Alqahtani AN, Alshehri FS, et al
    Defining and managing high-risk acute myeloid leukemia (AML) in 2026.
    Ann Hematol. 2026;105:416.
    PubMed         Abstract available

  8. ADNAN N
    Presenting a multi-marker response-adapted framework for venetoclax duration in acute myeloid leukemia.
    Ann Hematol. 2026;105:414.
    PubMed        


    Blood

  9. BERTOLI S, Landberg N, Berard E, Gondran C, et al
    Intensive Chemotherapy and Tyrosine Kinase Inhibitor in Patients with De Novo BCR::ABL1+ Acute Myeloid Leukemia.
    Blood. 2026 Sep 18:blood.2026033895. doi: 10.1182/blood.2026033895.
    PubMed         Abstract available


  10. Sasca D, Hahnel PS, Szybinski J, et al. SIRT1 prevents genotoxic stress-induced p53 activation in acute myeloid leukemia. Blood. 2014;124(1):121-133.
    Blood. 2026;148:1637-1638.
    PubMed        

  11. KENNEDY VE, Peretz CAC, Walia A, Chyla B, et al
    Dynamic genetic and nongenetic RAS-pathway activation drives resistance to FLT3 and BCL2 inhibitor therapy.
    Blood. 2026;148:1588-1604.
    PubMed         Abstract available


    Cancer

  12. CHIEN KS, Garcia-Manero G
    Clinical management of clonal hematopoiesis.
    Cancer. 2026;132:e70588.
    PubMed         Abstract available

  13. ZHANG J, Luo J, Shen X, Ren J, et al
    Timing matters: Impact of covalent BTK inhibitor dose modifications on outcomes in chronic lymphocytic leukemia/small lymphocytic leukemia-A 7-year real-world study.
    Cancer. 2026;132:e70578.
    PubMed         Abstract available

  14. SENAPATI J, Abdel-Salam HM, Jdanov VD, Loghavi S, et al
    Outcomes of adult patients with Li-Fraumeni syndrome and myeloid neoplasms.
    Cancer. 2026;132:e70613.
    PubMed         Abstract available


    Cancer Chemother Pharmacol

  15. TANNUMSAENG S, Anurathapan U, Sermcheep A, Kanjanakan P, et al
    Outcomes of locally produced donor-derived anti-CD19 chimeric antigen receptor T-cells in relapsed or refractory B-cell acute lymphoblastic leukemia patients.
    Cancer Chemother Pharmacol. 2026;96:107.
    PubMed         Abstract available


    Exp Hematol

  16. FENG J, Hao Q, Xu M, Jia Y, et al
    Effect of the dominant-negative Ikaros isoform 6 (Ik6) on cell function and drug sensitivity in Ph-positive acute lymphoblastic leukemia cell lines.
    Exp Hematol. 2026 Sep 13:105871. doi: 10.1016/j.exphem.2026.105871.
    PubMed         Abstract available

  17. KIM HN, Hurwitz S, Fourfouris T, Lee KJ, et al
    Integrin Alpha 4 Inhibition Prolongs the Survival of NSG Mice Engrafted with CD19-Negative Post-CART19 Relapsed B-ALL.
    Exp Hematol. 2026;161:105471.
    PubMed         Abstract available


    Int J Hematol

  18. HASEGAWA K, Miyazaki T, Tanaka M, Hagihara M, et al
    Dynamic nutritional changes between relapse and second allogeneic transplantation predict survival in acute leukemia.
    Int J Hematol. 2026 Sep 18. doi: 10.1007/s12185-026-04279.
    PubMed         Abstract available

  19. VOLKOV N, Moiseev I, Botina A, Zhogolev D, et al
    Cytokine release syndrome in adults with acute leukemia after allo-HCT with posttransplant cyclophosphamide prophylaxis.
    Int J Hematol. 2026 Sep 15. doi: 10.1007/s12185-026-04287.
    PubMed         Abstract available


    J Clin Oncol

  20. POLLARD JA, Alonzo TA, Gerbing RB, Kutny M, et al
    AAML1831: A Phase III Trial Comparing Standard Induction Therapy With CPX-351 in De Novo Pediatric AML: A Report From the Children's Oncology Group.
    J Clin Oncol. 2026;44:2590-2601.
    PubMed         Abstract available


    Leuk Lymphoma

  21. BORRAS-BLASCO J, Valcuende-Rosique A, Cornejo-Uixeda S
    Letter to the editor regarding 'Real-world venetoclax dosing patterns and treatment persistence in patients with acute myeloid leukemia: a community pharmacy database study in Japan'.
    Leuk Lymphoma. 2026 Sep 16:1-2. doi: 10.1080/10428194.2026.2732486.
    PubMed        

  22. DAUNOV M
    Expanding access to leukemia specialists in the venetoclax era.
    Leuk Lymphoma. 2026 Sep 13:1-3. doi: 10.1080/10428194.2026.2731270.
    PubMed        

  23. SCHOENBECK K, Wei D, Hazra NC, Constantinescu C, et al
    Adverse events, quality of life, and work impairment in patients with chronic myeloid leukemia (CML)-a survey of first- and second-line tyrosine kinase inhibitor (TKI) intolerance in the US.
    Leuk Lymphoma. 2026 Sep 13:1-11. doi: 10.1080/10428194.2026.2721033.
    PubMed         Abstract available


    Leuk Res

  24. RESTO-SANTOS DM, Perissinotti AJ, Bixby DL, Burke PW, et al
    Treatment of acute myeloid leukemia with inv(3) or t(3;3): A single-center retrospective cohort study and literature review.
    Leuk Res. 2026;170:108319.
    PubMed         Abstract available


    Leukemia

  25. GURU MURTHY GS, Shah B, Badar T, Leonard J, et al
    Targeting CD38 with bispecific antibody XmAb 18968 in patients with relapsed/refractory acute myeloid leukemia and T-cell acute lymphoblastic leukemia.
    Leukemia. 2026 Sep 14. doi: 10.1038/s41375-026-03130.
    PubMed         Abstract available


    N Engl J Med

  26. MYERS RM, Hunger SP
    Blinatumomab - A New Standard of Care in Acute Lymphoblastic Leukemia.
    N Engl J Med. 2026;395:1127-1129.
    PubMed        

  27. SCHRAPPE M, Locatelli F, Valsecchi MG, Zugmaier G, et al
    Blinatumomab for Replacing Chemotherapy in Pediatric Acute Lymphoblastic Leukemia.
    N Engl J Med. 2026;395:1075-1089.
    PubMed         Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Leukemia is free of charge.

Privacy / Datenschutzerklärung | Imprint / Impressum